IGC Pharma (IGC) Common Equity (2011 - 2026)

IGC Pharma (IGC) has reported Common Equity for 16 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Common Equity fell 3.3% year-over-year to $6.1 million in Q1 2026; TTM through Mar 2026 was $6.1 million, a 3.3% decrease from a year earlier, with the FY2026 full-year figure at $6.1 million, down 3.3% from the prior year.
• Common Equity was $6.1 million for Q1 2026 at IGC Pharma, down from $7.4 million in the prior quarter.
• Over five years, Common Equity peaked at $23.9 million in Q1 2022 and troughed at $6.1 million in Q2 2025.
• A 5-year average of $11.7 million and a median of $8.1 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity tumbled 50.9% in 2024 and rose 18.6% in 2025, its largest moves.
• Over 5 years, Common Equity stood at $18.3 million in 2022, then sank by 50.58% to $9.1 million in 2023, then sank by 30.86% to $6.3 million in 2024, then increased by 18.6% to $7.4 million in 2025, then decreased by 17.54% to $6.1 million in 2026.
• The last three Common Equity figures came in at $6.1 million (Q1 2026), $7.4 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.